Abstract 639P
Background
Maintenance therapy with fluoropyrimidines (such as capecitabine [Cap]) following induction therapy is wildly recommended to unresectable mCRC patients. Fruquintinib (Fru) is a highly selective inhibitor of VEGFR1/2/3 with conspicuous safety and efficacy in mCRC. We sought to evaluate and compare the therapeutic potential of Fru plus Cap (FC) versus Cap as maintenance therapy for mCRC.
Methods
Eligibility criteria included: histologically confirmed mCRC (stage IV), age ≥ 18 years, ECOG PS 0-2, achieved disease control (including CR/PR and SD) after ≥ 6 cycles of first-line standard chemotherapy and still unresectable. In safety lead-in phase (SP), patients (pts) were orally administered with Fru (4 mg, QD, d1-21, Q4W) plus Cap (850 mg/m2, BID, d1-7 and d15-21, Q4W). In expansion phase, pts were randomized in a 1:1 ratio between FC (Arm A) and Cap (Arm B) only. The primary objectives were to characterize safety, confirm the recommended phase 2 dose (RP2D; in phase SP), and evaluate the efficacy (in phase EP).
Results
As of April 24, 2023, 22 pts were enrolled (SP: n = 6; EP: Arm A/B n/n = 7/7). In phase SP, 1 pt experienced DLT of grade 3 oral mucositis. The treatment emergent AEs (TEAEs, Grade ≥3) were hypertension (1/6), oral mucositis (1/6), voice alteration (1/6), small intestinal obstruction (1/6) and blood bilirubin increased (1/6). After full consideration about patient’s tolerance and safety, the RP2D of Fru was adjusted from 4mg to 3mg through charrette. In Arm A, the most common TEAEs (Grade ≥3) were merely hypertension and leukopenia. Intriguingly, these results provided further evidence that reducing RP2D from 4 mg to 3mg can ensure the safety and tolerance. In 6 evaluable pts of phase SP, the DCR was 100% while the mPFS was immaturity, but 3 pts showed the PFS of ≥ 6 months (7.5, 8.6, 8.9 mon, respectively).
Conclusions
The combination of fruquintinib plus capecitabine demonstrated an acceptable tolerability profile. Preliminary antitumor activity was observed in pts with mCRC that revealed promising efficacy and safety as a first-line maintenance therapy. Dose expansion is ongoing at the RP2D in dedicated mCRC.
Clinical trial identification
NCT05451719.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11